Involvement of the dopamine nigrostriatal system in the picrotoxin effect on striatal acetylcholine levels

Cholinergic connectivity: it's implications for psychiatric disorders

Acetylcholine has been implicated in both the pathophysiology and treatment of a number of psychiatric disorders, with most of the data related to its role and therapeutic potential focusing on schizophrenia. However, there is little thought given to the consequences of the documented changes in the cholinergic system and how they may affect the functioning of the brain. This review looks at the cholinergic system and its interactions with the intrinsic neurotransmitters glutamate and gamma-amino butyric acid as well as those with the projection neurotransmitters most implicated in the pathophysiologies of psychiatric disorders; dopamine and serotonin. In addition, with the recent focus on the role of factors normally associated with inflammation in the pathophysiologies of psychiatric disorders, links between the cholinergic system and these factors will also be examined. These interfaces are put into context, primarily for schizophrenia, by looking at the changes in each of these systems in the disorder and exploring, theoretically, whether the changes are interconnected with those seen in the cholinergic system. Thus, this review will provide a comprehensive overview of the connectivity between the cholinergic system and some of the major areas of research into the pathophysiologies of psychiatric disorders, resulting in a critical appraisal of the potential outcomes of a dysregulated central cholinergic system.

Activation of GABAA receptor in the brain suppresses neostigmine or histamine-induced central nervous system-mediated hyperglycemia

We investigated the effect of GABA receptor agonists on the central nervous system (CNS)-mediated hyperglycemia induced by neostigmine or histamine in anesthetized fed rats. The injection of muscimol, GABAA receptor agonist (1, 2.5 nmol) into the third cerebral ventricle suppressed the hyperglycemia induced by intraventricular injection of neostigmine (1 x 10(-8) mol) or histamine (5 x 10(-7) mol). Baclofen, GABAB receptor agonist (1, 2.5 nmol), however, did not suppress these hyperglycemia. Neither muscimol nor baclofen (2.5 nmol) affected plasma glucose levels. These findings suggest that activation of GABAA receptor in the CNS suppresses the hyperglycemia induced by the stimulation of cholinoceptive neuron or histaminergic neuron, but activation of GABAB receptor does not affect them.

Muscarinic receptors mediate direct inhibition of GABA release from rat striatal nerve terminals

The effects of acetylcholine (ACh) on the depolarization-evoked release of [3H]gamma-aminobutyric acid ([3H]GABA) have been investigated using synaptosomes prepared from rat corpus striatum and depolarized by superfusion with 9 mM KCl. Acetylcholine inhibited the [3H]GABA overflow in a concentration-dependent manner. The maximal effect was about 50%. The IC50 value (concentration producing half-maximal effect) amounted to 1 microM, in the absence of acetylcholinesterase inhibitors. The effect of ACh on the K(+)-evoked [3H]GABA release was counteracted by the muscarinic receptor antagonist atropine, but not by the nicotinic receptor antagonist mecamylamine or by the selective M1 antagonist pirenzepine. The data show that muscarinic receptors with low affinity for pirenzepine are localized on GABAergic nerve endings in rat corpus striatum where they may directly inhibit the release of GABA.

Effects of acute and subacute administration of bicuculline on dopamine and muscarinic receptors in rat brain

The changes of characteristics of dopamine (D1 and D2) and muscarinic receptors after acute and subacute administration of bicuculline were examined in rat brain. The results demonstrated that in striatal region, the Bmax of D2 receptor was significantly increased with no change of affinity after subacute administration of bicuculline. However, neither Bmax nor Kd or the D2 receptor was changed after single administration. The characteristics of D1 receptor were not changed by either acute or subacute administration. The Bmax of muscarinic receptor in striatal area was significantly increased without changes of affinity after both a single and repeated administration of bicuculline. However, in hippocampus, the Bmax of muscarinic receptor was significantly decreased after subacute administration of bicuculline. The results suggest that the interactions among GABAergic, dopaminergic and cholinergic neuron exist in central nerve system.

Blockade of the diazepam-induced increase in rat striatal acetylcholine content by the specific benzodiazepine antagonists ethyl-beta-carboline-3-carboxylate and Ro 15-1788

Diazepam increased the acetylcholine content in the striatum and the hippocampus of the rat. This effect was antagonized in both brain areas by treatment with the specific central benzodiazepine blockers ethyl-beta-carboline-3-carboxylate and Ro 15-1788, whereas the peripheral antagonist Ro 5-4864 was ineffective. Pretreatment with picrotoxin, a known GABA antagonist did not interfere with the diazepam-induced acetylcholine increase. These results indicate a specific involvement of benzodiazepine receptors in the cholinergic action of diazepam and this effect appears to be independent of GABA receptor activation.

GABAergic regulation of the substantia innominata-cortical cholinergic pathway

Neurochemical and immunohistocytochemical studies have demonstrated a nucleus accumbens-substantia innominata GABAergic pathway. The present authors' data with muscimol given parenterally, as well as local injections into the substantia innominata, further support an inhibitory function for this pathway in the regulation of the substantia innominata-cortical cholinergic projection.

GABA induced changes in acetylcholine release from slices of guinea-pig brain

The effect of GABA on acetylcholine (ACh) release was investigated on superfused slices of guinea-pig cerebral cortex (CC), caudate nucleus (CN), tuberculum olfactorium and brain stem. GABA (1--6 x 10(-3) mol/l) increased the spontaneous and KCl-evoked ACh overflow in CC and CN, reduced the electrically-evoked release in all areas tested (most evidently in CC and CN) and lowered the threshold of electric stimulation-induced ACh release in CC. These effects were also caused by 3-amino-1-propane sulphonic acid (1 x 10(-3) mol/l) and ethanolamine-O-sulphate (2 x 10(-3) mol/l), were reduced by bicuculline (1 x 10(-4) mol/l) and fully antagonized by picrotoxin (8 x 10(-5) mol/l), but they were not influenced by phentolamine, methysergide, spiroperidol or strychnine. Tetrodotoxin (TTX) (5 x 10(-7) mol/l) blocked the facilitation of spontaneous ACh release by GABA only when the slices were perfused with normal Krebs solution, but not when perfused with a KCl-enriched medium. These results suggest that GABA affects the cholinergic transmitter release through bicuculline- and picrotoxin-sensitive receptors, showing low affinity toward the agonist. Moreover GABA modulation of resting ACh release requires action potentials only in normal [K+]0, but not in high [K+]0, suggesting that GABA-receptive sites are located at cholinergic terminals.

Selected ion monitoring determination of acetylcholine during methoxypyridoxine seizures

The neurotransmitter gamma-aminobutyric acid is known to decrease preictally after administration of the potent convulsant methyoxypyridoxine, a competitive inhibitor of glutamate decarboxylase. An attempt was made to determine the effect of this gamma-aminobutyric acid decrease on the cholinergic system. Rabbits were immobilized and artificially ventilated in order to avoid hypoxidosis. Seizures were induced by intravenous injection of 100 mg kg-1 methoxypyridoxine; 40 minutes later the animals were decapitated and discrete brain areas removed. Tissue contents of acetylcholine and choline were estimated by gas chromatographic mass spectrometric analysis of the beta-dimethylaminoethyl acetate and propionate derivatives using deuterated internal standards. Gas chromatographic column optimization resulted in a considerable sensitivity gain. Computerized selected ion monitoring was carried out on the dimethylmethyleneimmonium ions using voltage switching. The use of a computer controlled solvent dump valve was implemented to increase precision. No significant difference was observed in the concentration of acetylcholine in the frontal cortex, cerebellar cortex, septum, hippocampus, or caudate of seizure versus control animals; septal choline increased, however. This suggests that the acetylcholine turnover could be increased during seizure.

Alterations in neurotransmitter function during the development of ethanol tolerance and dependence

Current studies demonstrate that alcohol tolerance and alcohol dependence are neurochemically dissociable processes. Development of tolerance seems to be accompanied by changes in neuronal membrane structure which, in turn, affects the function of membrane-bound dopaminergic receptors. On the other hand, changes in cholinergic receptor number in certain brain areas may be responsible for certain signs of physical dependence during ethanol withdrawal.

Receptor and membrane function in the alcohol tolerant/dependent animal

Neurochemical changes which are associated with the development or expression of tolerance to or physical dependence on ethanol may be expected to display a time course of appearance and disappearance which correlates positively with the time course for tolerance or dependence. Previous studies of striatal dopaminergic receptor function indicated that ethanol-withdrawn mice displayed decreased physiological and biochemical responses to dopamine (DA) agonists, which could be best explained by postulating an inefficient coupling between DA receptors and various receptor-mediated processes, possibly as a result of ethanol-induced changes in neuronal membrane properties. The membrane-bound enzyme, (Na+-K+)ATPase, obtained from ethanol-withdrawn animals, displays an altered transition temperature and resistance to the effects of ethanol on enzyme activity. These changes also suggest compensatory alterations in neuronal membrane properties. All of these alterations show a time course of disappearance which corresponds to that for the disappearance of tolerance to the hypothermic and sedative effects of ethanol. Ethanol-withdrawn mice also display increased numbers of hippocampal muscarinic cholinergic receptors; however, the time course for the increase in receptor number appears to correlate with that of withdrawal symptomatology. Thus, compensatory changes in neuronal membrane properties in response to ethanol may be expressed via diverse functional changes.

Alterations in neurotransmitter activity after acute and chronic ethanol treatment: studies of transmitter interactions

Acute and chronic ethanol treatment has multiple effects on the neurotransmitter systems in the nigrostriatal complex. A single dose of ethanol increases striatal dopamine release at low doses, but depresses it at high doses. In ethanol-dependent rats, dopamine release is accelerated during intoxication, but is reduced during a withdrawal syndrome. Concomitantly, high-affinity choline uptake, an index of cholinergic activity, is elevated at times when dopamine release is depressed. Changes in dopaminergic or cholinergic receptor activity do not induce or result from these effects. Neither has a role for GABA or substance P yet been implicated. The data suggest that interactions between at least two trasmitters in the caudate nucleus may occur after acute and chronic ethanol treatment.

The effect of gamma-butyrolactone on locomotor activity in the rat

The effect of gamma-butyrolactone (GBL) on locomotor activity in the rat was studied. Low doses of GBL (100 and 200 mg/kg) had a biphasic effect on activity. Initially, the activity of the rats was reduced, and this reduction was then followed by a period of hyperactivity. The effect of alpha-flupenthixol (50 microgram/kg alpha-FPT), atropine (10 mg/kg), benztroine (25 mg/kg), protriptyline (15 mg/kg), and clomipramine (25 mg/kg) was investigated on this biphasic effect. alpha-FPT reduced the hyperactivity while benztropine potentiated it; atropine, clomipramine, and protriptyline had little effect. It is concluded that the increase in activity could be due to a release of dopamine.

Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats

In otherwise profoundly akinetic rats that had been severely depleted of brain catecholamines, anticholinergic drugs caused excessive walking. The effect did not appear until 10 days after surgery and then increased with time, suggesting that a phenomenon analogous to denervation supersensitivity may be involved. If the animals walked into corners, they were unable to turn around or back out. Their gait (extremely short steps) was reminiscent of that of patients with Parkinson's disease. The results are consistent with a mutually antagonistic interaction between cholinergic and dopaminergic brain systems and emphasize certain complexities in this interaction.